A 55-year-old man (height = 175 cm, weight = 68 kg, Body Mass Index = 22.2 kg/ m 2 ) came to our observation in December 2012 due to the onset of bone pain, muscle cramps, and asthenia. Past history revealed that about 24 years before (1988) a chronic hepatitis B (anti-HBe positive) infection was diagnosed and 15 years later (2003) liver biopsy and endoscopy documented the presence of cirrhosis (Child 5A) with esophageal varices, respectively.
the persistence of serum HBV-DNA levels (1025 IU/ml) was recorded, therefore adefovir (10 mg/day) was added, thus attaining a virological suppression in about 2 months (HBV-DNA < 200 IU/ml).
On February 2008, during the follow-up, an increase in serum HBV-DNA levels was detected (3770 IU/ml), lamivudine was stopped and entecavir (1 mg/day) was added with a complete suppression in three months (HBV-DNA undetectable). The history of HBV infection and the related treatments are reported in Table I , while Figure 1 shows the correlation between HBV-DNA levels and drug treatments.
On December 2010, biochemical evaluations revealed hypophosphoremia and glycosuria, without hyperglycemia (Table II) .
On March 2011, the patient lamented muscular pain with walking difficulties and lower sensitivity in lower limbs and on Feb- T-score = -4.2, Z-score = -3.3; left total hip = 0.423 g/cm 2 , T-score = -4.2, Z-score = -3.3). Arterial blood gas showed metabolic acidosis, while blood chemical evaluation revealed high levels of serum creatinine, phosphate, alkaline phosphatase and parathyroid hormone level, and low levels of creatinine clearance, phosphorus and potassium. Moreover, using a reversed phase (C18) high-performance liquid chromatography system (HPLC; UV detector 265 nm, limit of detection 1,5 ng/ml; intra-assay and inter-assay coefficients of variation for control = 8%), low levels of 25-hydroxy-vitamin D and of 1-25-dihydroxy-vitamin D were detected.
Anion gap, serum albumin, serum-free T 4 and TSH were within the normal rang-es, while urinalysis showed high levels of proteins, glucose, potassium, calcium, and phosphate (see Table II ).
The kidney biopsy showed diffuse and severe tubulointerstitial nephritis with dense lymphoplasmocyte infiltrates. The absence of nausea, diarrhea, abnormal stools, weight loss, and gas, after 1 week of diet with standard food, as well as immunoglobulin A anti-tissue transglutaminase antibody evaluation (for celiac disease) and hydrogen breath test (for lactose intolerance) excluded a malabsorption syndrome.
A diagnosis of Fanconi syndrome with hypophosphatemic osteomalacia was postulated and using the Naranjo probability scale [1] we documented a possible association between adefovir and proximal tubulopathy (score = 7). Adefovir was dismissed after 27 months, which was mild in 77.8% of patients, moderate in 20.8%, and severe in one patient.
In agreement, Li et al. [17] reported a case of a patient that developed Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness 4 years after the beginning of adefovir.
In our case, renal disease became symptomatic 67 months after the beginning of adefovir, with the development of musculoskeletal pain and difficulty in walking. The nephrotoxicity of adefovir is characterized by a decrease in serum phosphate levels with a modest increase in serum creatinine, related to proximal renal tubules dysfunction, as documented through laboratory texts.
Respect to other papers [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] that reported the association between adefovir and renal-toxicity, in the present case, using HPLC, we documented low plasma levels of vitamin D responsible of femoral fractures after an accidental fall related to muscle cramps.
Previously, Tanaka and colleagues [18] reported a 62-year-old man that developed pathological femoral fractures due to osteomalacia after 5 years from the beginning of adefovir, without deficiency of vitamin D.
Moreover, the development of hypophosphatemic osteomalacia associated with tenofovir has been also reported [19] [20] [21] and its features are similar to those of hypophosphatemic osteomalacia documented in our patient.
Some Authors documented that proximal renal tubules dysfunction, reducing the absorption of amino acids, glucose, bicarbonate, and phosphate, and the synthesis of 1,25-diidroxy-vitamin D3, induces the development of hypophosphatemic osteomalacia and Fanconi syndrome. Low levels of vitamin D increase the risk of bone loss, muscle aches, cramps, and fatigue [22, 23] .
The dismission of adefovir and the treatment with vitamin D induced the improvement of symptoms with the normalization of laboratory findings.
(HBV-DNA < 200 IU/mL), bicarbonates (12 mEq/day) and vitamin D (100,000 UI/ day for 7 days and then 800 UI/day) were added with an improvement of muscular pain in two months (VAS = 2); the inability to walk disappeared in about six months, with normalization of laboratory text.
On October 2014, the patient was in entecavir monotherapy, microbiology assay documented a suppression of HBV-DNA (< 200 IU/mL) and no side effects were recorded. A new follow-up performed on December 2014 revealed a significant improvement of both bone max density (DXA L1-L4 = 1.532 g/cm 2 , T-score = 1.6, Z-score = 2.3; and left hip = 0.758 g/cm 2 , T-score = -2.3, Z-score = -1.7) and biochemical assays (Table II) .
DISCUSSION
Adefovir dipivoxil is a nucleotide analog reverse transcriptase inhibitor used to treat adult patients affected by HBeAg-positive and HBeAg-negative chronic hepatitis B and with clinical evidence of lamivudine-resistant hepatitis B virus (HBV) [2, 3] .
We report the development of tubules renal toxicity with osteomalacia and Fanconi syndrome during adefovir treatment.
Renal toxicity during the treatment with adefovir at the dosage of 30-120 mg/day is uncommon; and some papers revealed that adefovir administered at common dosage of 10 mg/day is well tolerated and does not cause alterations in creatinine clearance compared to placebo [4, 5] .
However, a long-time treatment can result in an increase in serum creatinine in about 6-8% of patients [6, 7] , or in the development of renal toxicity [8] [9] [10] [11] [12] [13] [14] [15] .
Kim and colleagues [16] , evaluating retrospectively 687 chronic hepatitis B patients treated with adefovir alone (18.2%) and urinary analysis should be carefully evaluated in order to prevent the development of serious adverse drug reaction. Moreover, as well reported by De Socio et al. [21] for tenofovir, in presence of osteomalacia-related to adefovir a multidisciplinary approach is important in order to perform a rapid diagnosis and a timely treatment.
Key points
y Adefovir is effective and generally well tolerated at the dosage of 10 mg/day y Even if unusual, the onset of renal toxicity may occur y In presence of muscle pain, it is necessary to check the renal function and the level of vitamin D y Renal function and vitamin D value must be carefully evaluated during the follow-up y In the suspect of adefovir toxicity, it is advisable to replace it with another antiviral drug in agreement with guidelines
In agreement with our previous paper [24] [25] [26] , using the Naranjo score, we documented a probable association between adefovir and clinical symptoms.
Treatment with entecavir in monotherapy maintained the viremic suppression without the development of side effects.
In conclusion, in patients with chronic hepatitis B treated with adefovir, blood
